+ Filter
Loading...
Custom Services order now ship next day

Anti-RET Recombinant Antibody Products

Loading...

Anti-RET Products

More Infomation

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs offers a series of high-quality anti-RET recombinant antibodies to advance global customers’ research projects. Based on our cutting-edge antibody engineering platform, these antibodies exhibit excellent sensitivity and excellent specificity, making them the optimal selection for diverse research application.

RET: A Versatile Immunotherapeutic Target

The RET (REarranged during Transfection) proto-oncogene is constitutively activated through structural reconfiguration, wherein its 3' tyrosine kinase domain undergoes genetic recombination with the 5' regions of partner genes encoding dimerization motifs, such as coiled-coil domains. Such oncogenic fusions have been identified across multiple malignancies, including carcinomas of the thyroid, lung, colorectal tissue, breast, and salivary glands. Functional genetic analyses reveal RET's indispensable contributions to enteric nervous system formation, renal organogenesis, and germ cell maturation. Ongoing investigations into RET-mediated signaling pathways continue to yield critical insights, bridging molecular oncology with fundamental studies of neural development and tissue morphogenesis.

Alternative Names

RET proto-oncogene; ret proto-oncogene; Ret; PTC; RET51; RET9; c-Ret; CDHF12; CDHR16; HSCR1; MEN2A; MEN2B; MTC1; RET-ELE1.

Background

This gene encodes a transmembrane receptor and member of the tyrosine protein kinase family of proteins. Binding of ligands such as GDNF (glial cell-line derived neurotrophic factor) and other related proteins to the encoded receptor stimulates receptor dimerization and activation of downstream signaling pathways that play a role in cell differentiation, growth, migration and survival. The encoded receptor is important in development of the nervous system, and the development of organs and tissues derived from the neural crest. This proto-oncogene can undergo oncogenic activation through both cytogenetic rearrangement and activating point mutations. Mutations in this gene are associated with Hirschsprung disease and central hypoventilation syndrome and have been identified in patients with renal agenesis.

Protein class

Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins

Predicted location

Intracellular, Membrane (different isoforms)

Single cell type specificity

Group enriched (Horizontal cells, Ionocytes, Skeletal myocytes)

Immune cell specificity

Not detected in immune cells

Cell line specificity

Cell line enhanced (MCF7, NB-4, SH-SY5Y, THP-1)

Interaction

Phosphorylated form interacts with the PBT domain of DOK2, DOK4 and DOK5 (By similarity). The phosphorylated form interacts with PLCG1 and GRB7 (By similarity). Interacts (not phosphorylated) with PTK2/FAK1 (via FERM domain) (PubMed:21454698). Extracellular cell-membrane anchored RET cadherin fragments form complex in neurons with reduced trophic status, preferentially at the contact sites between somas (PubMed:21357690). Interacts with AIP in the pituitary gland; this interaction prevents the formation of the AIP-survivin complex (PubMed:19366855). Binds to ARTN (By similarity). Interacts (inactive) with CBLC and CD2AP; dissociates upon activation by GDNF which increases CBLC:CD2AP interaction (PubMed:18753381). Interacts (via the extracellular domain) with GFRAL (via the extracellular domain); the interaction mediates cellular signaling upon interaction of GFRAL with its ligand GDF15 (PubMed:28953886, 28846097, 28846099). Interaction with GFRAL requires previous GDF15-binding to GFRAL (PubMed:28846097, 28846099). Interacts with GFRA1; in the presence of SORL1, the GFRA1/RET complex is targeted to endosomes (PubMed:23333276). Interacts with GDNF (PubMed:21994944).

Molecular function

Kinase, Transferase, Tyrosine-protein kinase

More Types Infomation

Anti-RET rAb Products

Creative Biolabs delivers engineered recombinant antibodies targeting RET, meticulously optimized for high-affinity binding and molecular specificity. These adaptable formats serve multifaceted applications spanning immunological studies, oncological investigations, and drug development pipelines. Production workflows incorporate rigorous quality control systems, reinforced by multidimensional validation protocols encompassing epitope mapping and functional characterization. By synthesizing molecular engineering innovations with standardized quality frameworks, the platform generates antibody reagents with enhanced target discrimination, binding stability, and methodological reproducibility—ensuring experimental reproducibility across fundamental and translational research applications.

Table 1. Featured anti-RET recombinant antibody products at Creative Biolabs.

Cat. No. Product Name Target Species Host Species Applications
ZG-0546U Rabbit Anti-RET Recombinant Antibody (clone 8D12) (CAT#: ZG-0546U) Human Rabbit IgG ELISA, FC
ZG-066R Mouse Anti-RET Recombinant Antibody (ZG-066R) Human Mouse IgG WB, ELISA
ZG-065R Mouse Anti-RET Recombinant Antibody (ZG-065R) Human Mouse IgG WB, ELISA
VS3-XY1369 Mouse Anti-RET Recombinant Antibody (clone 8D10C9) Human Mouse IgG1 WB, ELISA
TAB-066MZ Anti-Human RET Recombinant Antibody (Y078) Human Human antibody Cyt, IHC, FC

Creative Quality Control

Creative Biolabs employs multistage quality assurance protocols to engineer anti-RET recombinant antibodies with high specificity and robust binding kinetics. Rigorous analytical validation ensures consistent functional performance of these biologics across diverse experimental systems, supported by standardized testing methodologies to confirm reproducibility in research applications.

Fig.1 FC analysis. (Creative Biolabs Original)Fig.1 FC analysis of anti-RET antibody
(Cat# ZG-0546U, Creative Biolabs).

Fig.2 WB analysis. (Creative Biolabs Original)Fig.2 WB analysis of anti-RET antibody
(Cat# ZG-066R, Creative Biolabs).

Fig.3 WB analysis. (Creative Biolabs Original)Fig.3 WB analysis of anti-RET antibody
(Cat# ZG-065R, Creative Biolabs).

Customer Reviews

Excellent
Vi***a
Mouse Anti-RET Recombinant Antibody (clone 8D10C9) (VS3-XY1369)
In our IHC investigations, the anti-RET antibody we obtained behaved precisely as predicted and was of excellent quality. a consistent reagent for our investigation on cancer.
11/Jun/2023
Excellent
Ri***y
Mouse Anti-RET Recombinant Antibody (ZG-065R) (ZG-065R)
Creative Biolabs offers a very selective anti-RET antibody together with first-rate customer service. Working with it was simple and produced consistent, reliable findings in our Western blotting tests.
25/Sep/2024
Excellent
Mi***n
Rabbit Anti-RET Recombinant Antibody (VS3-CJ479) (VS3-CJ479)
We like Creative Biolabs' given versatility in antibody forms. The tailored antibody rapidly advanced our study on RET signaling pathways by exactly matching our particular experimental setting.
13/Nov/2024

rAb Production

Creative Biolabs provides a reliable global supply of high-quality anti-RET recombinant antibodies, meticulously developed through cutting-edge recombinant technology for research applications.

Featured Anti-RET Recombinant Antibody Production PlatformsFig.4 Milligram-scale. (Creative Biolabs Original)
Fig.4 Milligram-scale anti-RET recombinant antibody production.

Fig.5 Gram-scale. (Creative Biolabs Original)Fig.5 Gram-scale anti-RET recombinant antibody production.

rAb Modalities

Creative Biolabs offers high-quality, customisable anti-RET recombinant antibodies tailored to meet specific research needs. These antibodies are offered in various forms and are meticulously tailored to meet the specific needs of local, national, and global research communities.

Fig.6 RET antibody production and modalities. (Creative Biolabs Original)Fig.6 Full-length anti-RET recombinant antibody production and modalities.

RET-Targeted Drug Information

Table 2. Public drug targeting RET.

Company Research phase Classification Condition
Yuhan (Originator) Preclinical Fusion Proteins
Growth Factors
Polypeptides, from 41 AA
Obesity
Henan Institute of Science Technology (Originator) Preclinical Polypeptides, from 41 AA
Recombinant proteins
Parkinson's disease
Institut Gustave Roussy (Originator)
Universite Paris - Sud 11 (Originator)
Preclinical Small Interfering RNA (SiRNAs) Endocrine cancer
Universitaet Rostock (Originator) Preclinical Adenoviral Vectors
Gene Therapy
Cancer, thyroid, medullary
Shaoxing University (Originator) Biological Testing Pegylated Drugs
Prodrugs
Cancer
Infection, bacterial
Inflammatory disorders
Regeneron (Originator) Biological Testing Cancer Immunotherapy
Human Monoclonal Antibodies
Cancer
Zhejiang University (Originator) Biological Testing Camptothecins
Nanoparticles
Polymer-Drug Conjugates
Cancer
Hangzhou Cancer Hospital (Originator) Biological Testing Polymer-Drug Conjugates
Vitamin E Analogues
Cancer
Nektar Therapeutics (Originator) Biological Testing Polymer-Drug Conjugates Cancer

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

With extensive expertise in the antibody development sector, Creative Biolabs boasts years of exceptional experience in both antibody engineering and production. The performance of these antibodies is outstanding across a range of research applications. If you have an interest in our RET recombinant antibodies, we invite you to reach out to us for exclusive pricing information.

Go to compare

Go to compare